Ventyx Biosciences Investor Alert: Probe Launched into Proposed Eli Lilly Acquisition

Kahn Swick & Foti, LLC investigating adequacy of price and process in proposed $14 per share sale

Published on Feb. 5, 2026

Got story updates? Submit your updates here. ›

The law firm of Kahn Swick & Foti, LLC has launched an investigation into the proposed acquisition of Ventyx Biosciences, Inc. by Eli Lilly and Company. Under the terms of the deal, Ventyx shareholders would receive $14 per share in cash. KSF is seeking to determine if this consideration and the process that led to it are adequate, or if the price undervalues the company.

Why it matters

The investigation by KSF, led by former Louisiana Attorney General Charles C. Foti, Jr., aims to ensure that Ventyx shareholders receive fair value for their shares in the proposed sale to the pharmaceutical giant Eli Lilly. Shareholder lawsuits over merger and acquisition deals are common, and the outcome of this probe could impact the final terms of the transaction.

The details

Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory diseases. Eli Lilly, one of the world's largest pharmaceutical companies, has proposed acquiring Ventyx for $14 per share in cash. KSF is investigating whether this price adequately values Ventyx and whether the sales process was fair to shareholders.

  • The proposed acquisition was announced on February 6, 2026.

The players

Kahn Swick & Foti, LLC

A law firm that specializes in investigating mergers and acquisitions to ensure shareholders receive fair value.

Charles C. Foti, Jr.

The former Attorney General of Louisiana and a partner at Kahn Swick & Foti, LLC.

Ventyx Biosciences, Inc.

A clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory diseases.

Eli Lilly and Company

One of the world's largest pharmaceutical companies, which has proposed acquiring Ventyx Biosciences.

Got photos? Submit your photos here. ›

What they’re saying

“If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-vtyx/ to learn more.”

— Lewis S. Kahn, Managing Partner, Kahn Swick & Foti, LLC (Business Wire)

What’s next

KSF will continue its investigation into the proposed acquisition to determine if the $14 per share price and the sales process are fair to Ventyx shareholders. The firm may take legal action if it finds the transaction undervalues the company.

The takeaway

This investigation highlights the importance of shareholder protections in mergers and acquisitions, as investors seek to ensure they receive fair value for their holdings. The outcome could impact the final terms of the Eli Lilly-Ventyx deal and serve as a precedent for future transactions.